Subscribe To Our Free Newsletter |
Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year ago
The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocon’s stake dilution in Bicara Therapeutics.